399 related articles for article (PubMed ID: 31891878)
21. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Johnston S; Puhalla S; Wheatley D; Ring A; Barry P; Holcombe C; Boileau JF; Provencher L; Robidoux A; Rimawi M; McIntosh SA; Shalaby I; Stein RC; Thirlwell M; Dolling D; Morden J; Snowdon C; Perry S; Cornman C; Batten LM; Jeffs LK; Dodson A; Martins V; Modi A; Osborne CK; Pogue-Geile KL; Cheang MCU; Wolmark N; Julian TB; Fisher K; MacKenzie M; Wilcox M; Huang Bartlett C; Koehler M; Dowsett M; Bliss JM; Jacobs SA
J Clin Oncol; 2019 Jan; 37(3):178-189. PubMed ID: 30523750
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
23. Response evaluation with
Taralli S; Lorusso M; Scolozzi V; Masiello V; Marazzi F; Calcagni ML
Ann Nucl Med; 2019 Mar; 33(3):193-200. PubMed ID: 30569442
[TBL] [Abstract][Full Text] [Related]
24. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
25. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
26. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
27. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
28. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
29. Clinical Validity of 16α-[
van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
[TBL] [Abstract][Full Text] [Related]
30. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
31. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
33. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
34. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
36. Prospective Pilot Study of
Covington MF; Hoffman JM; Morton KA; Buckway B; Boucher KM; Rosenthal RE; Porretta JM; Brownson KE; Matsen CB; Vaklavas C; Ward JH; Wei M; Buys SS; Chittoria N; Yakish ED; Archibald ZG; Burrell LD; Butterfield RI; Yap JT
AJR Am J Roentgenol; 2023 Aug; 221(2):228-239. PubMed ID: 36919879
[No Abstract] [Full Text] [Related]
37. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
39. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
[TBL] [Abstract][Full Text] [Related]
40. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
